Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.
Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.
复制标题
DOI：
10.1007/s10555-013-9482-0
复制
发表时间：
2014-09
影响因子：
9.2
通讯作者：
Yu, Evan
中科院分区：
文献类型：
--
作者：
Wu, Jennifer;Yu, Evan
Prostate cancer is the most commonly diagnosed cancer in men and is the second leading cause of cancer-related deaths in men each year. Androgen-deprivation therapy is and has been the gold standard of care for advanced or metastatic prostate cancer for decades. While this treatment strategy initially shows benefit, eventually tumors recur as castration-resistant prostate cancer (CRPC) for which there are limited treatment options with only modest survival benefit. Upregulation of the insulin-like growth factor receptor type I (IGF-IR) signaling axis has been shown to drive the survival of prostate cancer cells in many studies. As many IGF-IR blockades have been developed, few have been tested pre-clinically and even fewer have entered clinical trials for prostate cancer therapy. In this review, we will update the most recent pre-clinical and clinical studies of IGF-IR therapy for prostate cancer. We will also discuss the challenges for IGF-IR targeted therapies to achieve clinical benefit for prostate cancer.
登录
查看更多内容
影响因子：
56.9
作者：
Chan, JM;Stampfer, MJ;Pollak, M
通讯作者：
Pollak, M
影响因子：
56.9
作者：
FUTREAL, PA;LIU, QY;WISEMAN, R
通讯作者：
WISEMAN, R
影响因子：
4.8
作者：
Chen, CF;Li, S;Lee, WH
通讯作者：
Lee, WH
影响因子：
5.6
作者：
Galet C;Gray A;Said JW;Castor B;Wan J;Beltran PJ;Calzone FJ;Elashoff D;Cohen P;Aronson WJ
通讯作者：
Aronson WJ
影响因子：
6.2
作者：
Chen, C;Lewis, SK;Weiss, NS
通讯作者：
Weiss, NS